liquid biopsy in breast cancer

Release time ：Dec-25,2024

Liquid biopsy is gaining increasing attention in the diagnosis of breast cancer. It assesses the presence and progression of cancer by detecting tumor cells or DNA in blood or other body fluids. This method is minimally invasive and highly repeatable, making it significantly valuable for early detection, treatment monitoring, and predicting recurrence.

Firstly, liquid biopsy can be utilized for early screening of breast cancer. Traditionally, breast cancer diagnosis has relied heavily on imaging and tissue biopsies, which may not detect all types of breast cancer at early stages. Liquid biopsy enhances early diagnostic accuracy by identifying circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) in the blood. Research indicates that liquid biopsy can, in some instances, detect breast cancer earlier than conventional imaging.

Secondly, liquid biopsy can monitor the efficacy of breast cancer treatments. During treatment, levels of CTCs and ctDNA in a patient's blood may fluctuate. Monitoring these changes allows physicians to more accurately evaluate treatment outcomes and adjust therapeutic strategies promptly. Additionally, liquid biopsy can predict the risk of breast cancer recurrence. Some studies have linked blood levels of CTCs and ctDNA to the risk of breast cancer recurrence, enabling physicians to identify patients at high risk for recurrence and implement appropriate preventative measures.

In conclusion, liquid biopsy, as an emerging diagnostic and monitoring tool for breast cancer, holds substantial clinical significance. With ongoing technological advancements and research, liquid biopsy is poised to become a crucial component of breast cancer management in the future. If you experience symptoms or have concerns regarding breast cancer, it is important to seek medical attention and consult with a healthcare professional without delay.